A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615).
Principal Investigator
Bradley Monk, MD
Status
Terminated
Date Opened To Accrual
December 13 2010
Date Closed to Accrual
March 16 2015
Date of Study Termination
February 09 2019
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To estimate the antitumor activity of elesclomol and paclitaxel in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer primarily through the frequency of objective tumor responses.
To determine the nature and degree of toxicity of elesclomol and paclitaxel in this cohort of patients.
Patient Population
Patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer primarily through the frequency of objective tumor responses.
Target Accrual
55
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.